(Reuters) - French drugmaker Genfit SA said on Thursday it will begin a late stage trial later thisyear of its lead treatment for a liver-destroying condition,saying it failed a midstage trial in part due to the prevalenceof patients with a mild form of the disease in the study.
The company said had it excluded data from those patientswith the mildest form of the disease known as NASH(non-alcoholic steatohepatitis) its drug, called GFT505, wouldhave been deemed effective in reversing the condition. Thecompany said it would likely include only more seriously illpatients in its planned much larger Phase III trials.
GFT505 also demonstrated a favorable effect on metabolicissues, lowering bad LDL cholesterol as well as unhealthy bloodfats called triglycerides and levels of blood glucose. NASH hasbeen closely associated with obesity and diabetes.
(Reporting by Ransdell Pierson and Bill Berkrot; Editing byChris Reese)
The company said had it excluded data from those patientswith the mildest form of the disease known as NASH(non-alcoholic steatohepatitis) its drug, called GFT505, wouldhave been deemed effective in reversing the condition. Thecompany said it would likely include only more seriously illpatients in its planned much larger Phase III trials.
GFT505 also demonstrated a favorable effect on metabolicissues, lowering bad LDL cholesterol as well as unhealthy bloodfats called triglycerides and levels of blood glucose. NASH hasbeen closely associated with obesity and diabetes.
(Reporting by Ransdell Pierson and Bill Berkrot; Editing byChris Reese)
via Smart Health Shop Forum http://ift.tt/1FN6R6w
No comments:
Post a Comment